Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Notes Payables (2016 - 2021)

Historic Notes Payables for BioRestorative Therapies (BRTX) over the last 11 years, with Q4 2021 value amounting to $250000.0.

  • BioRestorative Therapies' Notes Payables changed N/A to $250000.0 in Q4 2021 from the same period last year, while for Dec 2021 it was $250000.0, marking a year-over-year change of. This contributed to the annual value of $250000.0 for FY2021, which is N/A changed from last year.
  • According to the latest figures from Q4 2021, BioRestorative Therapies' Notes Payables is $250000.0.
  • BioRestorative Therapies' Notes Payables' 5-year high stood at $8.0 million during Q1 2020, with a 5-year trough of $250000.0 in Q4 2021.
  • Moreover, its 5-year median value for Notes Payables was $4.2 million (2018), whereas its average is $4.3 million.
  • Its Notes Payables has fluctuated over the past 5 years, first soared by 8183.38% in 2018, then tumbled by 4108.07% in 2021.
  • Over the past 5 years, BioRestorative Therapies' Notes Payables (Quarter) stood at $3.7 million in 2017, then increased by 13.32% to $4.1 million in 2018, then surged by 85.16% to $7.7 million in 2019, then grew by 4.4% to $8.0 million in 2020, then crashed by 96.88% to $250000.0 in 2021.
  • Its Notes Payables stands at $250000.0 for Q4 2021, versus $5.9 million for Q3 2021 and $5.0 million for Q2 2021.